Source: Annual Congress 2001 - Respiratory structure and function in COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Valente, G. Iuliano, G. Pezzuto, D. Spina, G. Gualano, K. Geraneo, S. Cardo, M. De Rosa, F. Varone, G. Ciappi, G. M. Corbo (Rome, Italy). Are bronchodilator drugs really useful in COPD?. Eur Respir J 2001; 16: Suppl. 31, 674

Member's Comments

No comment yet.

Related content which might interest you: Clinically important deteriorations in COPD as a measure of response to dual and mono bronchodilator therapy with and without inhaled corticosteroids Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 The role of bronchodilator treatment in the prevention of exacerbations of COPD Source: Eur Respir J 2012; 40: 1545-1554 Year: 2012 Bronchodilator treatment for asthma and COPD Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD Year: 2010 Is there a problem with inhaled corticosteroid use in COPD? Source: Virtual Congress 2020 – Airway diseases Year: 2020 What to use INSTEAD of inhaled corticosteroids in COPD? Source: Eur Respir J 2014; 44: 1391-1393 Year: 2014 How the bronchodilatator in COPD patients works Source: Eur Respir J 2004; 24: Suppl. 48, 288s Year: 2004 Comparison of the efficacy and safety of long-acting anticholinergic and a combination of inhaled steroids and long-acting beta-2 agonist in moderate chronic obstructive pulmonary disease Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 Long-acting bronchodilators in COPD: where are we now and where are we going? Source: Breathe 2014; 10:110-120 Year: 2014 Short-acting bronchodilator reversibility does not predict the response to long-term treatment by indacaterol 150 µg in COPD: REVERBREZ study Source: Annual Congress 2013 –Respiratory and cardiovascular abnormalities in COPD: the role of exercise, nutritional status and inflammation Year: 2013 The effect on mortality of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A focus on the frequent exacerbator phenotype Source: International Congress 2015 – COPD and lung function: risk factors and outcomes Year: 2015 Assessing bronchodilator response in patients with asthma and COPD using 19F-MRI Source: Virtual Congress 2020 – New imaging techniques applied to old problems Year: 2020 Bronchodilator therapies for severe asthma Source: Eur Respir Mon 2011; 51: 253-267 Year: 2011 Magnetocardiographic assessment of therapeutic efficacy of β2–agonists and corticosteroids in patients with COPD and bronchial asthma Source: Annual Congress 2008 - Comorbid cardiovascular condition and therapy of asthma Year: 2008 Suppression of FENO with observed inhaled corticosteroid therapy in severe asthma: is it a useful test in clinical practice? Source: ERJ Open Res, 5 (4) 00123-2019; 10.1183/23120541.00123-2019 Year: 2019 Clinical and inhaled drug profile of COPD patients with indication for beta-blockers who are on beta-blockers Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 lnhaled long-acting beta-agonists as an inhaled corticosteroid-sparing agent for chronic asthma in adults Source: Eur Respir J 2005; 26: Suppl. 49, 124s Year: 2005 Inhaled corticosteroid combined with long-acting bronchodilator versus long-acting bronchodilator alone for older patients with COPD Source: International Congress 2015 – Advances in pneumonia management, COPD therapy and lung nodule evaluation Year: 2015 Comparison of protective effect of bronchodilators in COPD Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Comparison of indacaterol with tiotropium or once-daily dual long-acting bronchodilator therapy with roflumilast for severe COPD Source: International Congress 2014 – Markers Year: 2014